🇺🇸 FDA
Patent

US 9029525

Compositions and methods for inhibiting expression of GSK-3 genes

granted A61PA61P21/00A61P25/00

Quick answer

US patent 9029525 (Compositions and methods for inhibiting expression of GSK-3 genes) held by Alnylam Pharmaceuticals, Inc. expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61P, A61P21/00, A61P25/00, A61P25/16, A61P25/18